Cas No.: | |
Chemical Name: | 4-(tert-butyl)-N-(3-(6-((4-(4-(6-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamido)hexyl)piperazine-1-carbonyl)phenyl)amino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)benzamide |
SMILES: | C(NC1=CC=CC(C2N=C(NC3=CC=C(C(N4CCN(CCCCCCNC(=O)CNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)=O)C=C3)C(=O)N(C)C=2)=C1C)(=O)C1=CC=C(C(C)(C)C)C=C1 |
Formula: | C55H62N10O8 |
M.Wt: | 991.163 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | DD-03-171 is a small molecule, CGI1746-based BTK degrader (PROTAC, biochemical IC50=5.1 nM) that efficiently degrade C481S-BTK, exhibits enhanced anti-proliferative effects on mantle cell lymphoma (MCL) cells in vitro by degrading BTK, IKFZ1 and IKFZ3; also displays efficacy against patient-derived xenografts in vivo. |